格隆汇1月13日丨贝康医疗-B(02170.HK)发布公告，截至2024年12月31日止年度，集团实现收入约为人民币2.95–3.05亿元，同比增加约41.8%–46.6%。
收入增加主要由于以下原因所致：(i)集团收购新加坡BMX Holdco Pte. Ltd.后借助其覆盖全球的销售网络实现了国内自主开发产品的国际销售，推动了集团全球销售收入增长；(ii)于2024年，集团成功开发了重要的客户关系。例如，在北美，集团与Gattaca Genomics LLC订立了买卖协议以出售Geri®全时差培养箱，在中国，集团与上海菁华医疗管理股份有限公司签订战略合作协议以出售涵盖男科检测、胚胎培养，冷藏存储等在内的产品；及(iii)于2024年，集团取得了超低温存储仪 — 液氮存储系统(BSG800A、 BSG800C)、DA5000高通量基因测序仪和精子品质分析仪(BKA210)的医疗器械注册证书，进一步丰富集团产品管线，促进集团产品的市场渗透率和销售增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.